Precision for Value's Jackie DeAngelis Discusses Common Launch Mistakes


In a new commentary for, Precision for Value SVP and Managing Director Jackie De Angelis outlines some of the most common mistakes that hinder access when launching a new drug. Included in Jackie’s list are launching with a weak payer value message, failing to make a data-driven economic argument for access, and overlooking the pull-through challenge.

To read her commentary, please click here. 

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.